Research
Hormonal
GLP-1 receptor agonists (GLP-1RA) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular and renal benefits in T2D patients, whereas sulphonyureas are associated with increased cardiovascular mortality.
If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about GLP-1RA or SGLT2i medications, as they protect your heart and kidneys. Avoid sulphonyureas if possible, as they may increase cardiovascular risk.
StrongSupportsVERY_HIGH confidence
Therapies within the GLP-1RA and SGLT2i classes have the strongest evidence to support cardiovascular benefit in people with T2D... Compared with other treatments, sulphonyurea use in people with T2D was associated with increased cardiovascular and all-cause mortality.
Why this rating
Cites dedicated Cardiovascular Outcome Trials (CVOTs) and meta-analyses.
Source
Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
David M. Williams et al. · Dove Medical Press (Taylor and Francis Group) · 2022
narrative_reviewCited 102×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →